5-chloro-N2-(4-(piperazin-1-yl)phenyl)-N4-((tetrahydrofuran-2-yl)methyl)pyrimidine-2,4-diamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 5-chloro-N2-(4-(piperazin-1-yl)phenyl)-N4-((tetrahydrofuran-2-yl)methyl)pyrimidine-2,4-diamine
• 英文别名: 5-chloro-2-N-[4-(piperazin-1-yl)phenyl]-4-N-[(tetrahydrofuran-2-yl)methyl]pyrimidine-2,4-diamine；5-chloro-4-N-(oxolan-2-ylmethyl)-2-N-(4-piperazin-1-ylphenyl)pyrimidine-2,4-diamine
• 化学式: C₁₉H₂₅ClN₆O
• 分子量: 388.9
• InChiKey: QEIBQCGEIITGSB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  74.3
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2-四氢糠胺 在 三乙胺 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 1.66h， 生成 5-chloro-N2-(4-(piperazin-1-yl)phenyl)-N4-((tetrahydrofuran-2-yl)methyl)pyrimidine-2,4-diamine
  参考文献：
  名称：

  [EN] INHIBITORS OF ACK1/TNK2 TYROSINE KINASE
  [FR] INHIBITEURS DE LA TYROSINE KINASE ACK1/TNK2

  摘要：

  描述了癌症治疗和抗癌化合物。特别是，披露了Ack1酪氨酸激酶的抑制剂及其在癌症治疗中的应用。还披露了筛选新的Ack1酪氨酸激酶抑制剂的方法。在具体示例中，披露了具有I至IV式的化合物。

  公开号：

  WO2015021149A1

文献信息

• [EN] INHIBITORS OF ACK1/TNK2 TYROSINE KINASE<br/>[FR] INHIBITEURS DE LA TYROSINE KINASE ACK1/TNK2
  申请人：H LEE MOFFITT CANCER CT & RES

  公开号：WO2015021149A1

  公开（公告）日：2015-02-12

  Described are cancer therapies and anti-cancer compounds. In particular, disclosed are ihibitors of Ack1 tyrosine kinase and their use in the treatment of cancer. Methods of screening for new Ack1 tyrosine kinase inhibitors are also disclosed. In specifc example, compound having Formula I through IV are disclosed.

  描述了癌症治疗和抗癌化合物。特别是，披露了Ack1酪氨酸激酶的抑制剂及其在癌症治疗中的应用。还披露了筛选新的Ack1酪氨酸激酶抑制剂的方法。在具体示例中，披露了具有I至IV式的化合物。
• INHIBITORS OF ACK1/TNK2 TYROSINE KINASE
  申请人：H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.

  公开号：US20160176826A1

  公开（公告）日：2016-06-23

  Described are cancer therapies and anti-cancer compounds. In particular, disclosed are inhibitors of Ack1 tyrosine kinase and their use in the treatment of cancer. Methods of screening for new Ack1 tyrosine kinase inhibitors are also disclosed. In specific example, compound having Formula I through IV are disclosed.

  本文描述了癌症治疗和抗癌化合物。特别地，揭示了Ack1酪氨酸激酶抑制剂及其在癌症治疗中的应用。还披露了筛选新的Ack1酪氨酸激酶抑制剂的方法。具体例子中，揭示了具有I至IV式的化合物。
• Inhibitors of ACK1/TNK2 tyrosine kinase
  申请人：H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.

  公开号：US10017478B2

  公开（公告）日：2018-07-10

  Described are cancer therapies and anti-cancer compounds. In particular, disclosed are inhibitors of Ack1 tyrosine kinase and their use in the treatment of cancer. Methods of screening for new Ack1 tyrosine kinase inhibitors are also disclosed. In specific example, compound having Formula I through IV are disclosed.

  所述的是癌症疗法和抗癌化合物。 特别是公开了 Ack1 酪氨酸激酶的抑制剂及其在治疗癌症中的用途。 还公开了筛选新的Ack1酪氨酸激酶抑制剂的方法。 在具体实例中，公开了具有式I至式IV的化合物。
• BRD4-kinase inhibitors as cancer therapeutics
  申请人：H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.

  公开号：US10738016B2

  公开（公告）日：2020-08-11

  Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I through IV.

  本文公开了作为 BDR4 抑制剂的化合物及其在治疗癌症中的用途。还公开了筛选 BDR4 选择性抑制剂的方法。在某些方面，公开了式I至式IV的化合物。
• POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS
  申请人：H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.

  公开号：US20170226065A1

  公开（公告）日：2017-08-10

  Disclosed herein are compounds that are inhibitors of BRD4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BRD4 are also disclosed. In certain aspects, disclosed are compounds of Formula I-IV.